BUREAU-VERITAS
8.11.2021 18:55:08 CET | Business Wire | Press release
Envision Digital International Pte Ltd (“Envision Digital”), a Singapore-headquartered global Artificial Intelligence of Things (AIoT) technology leader for net zero, and Bureau Veritas , a world leader in testing, inspection and certification, will jointly develop net zero technology solutions helping businesses, organisations and governments around the world drive climate action, make meaningful progress on their net zero commitments, and do so in a standardized, certifiable, and verifiable manner.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211108005906/en/
Lei Zhang, Founder and CEO of Envision Group, commented:
“ “Through strategic partnership with Bureau Veritas, our best practices of digital solution will help more companies around the world accelerate their net zero transition. ”
Didier Michaud-Daniel, CEO of Bureau Veritas, added:
“Our role as an independent third party is essential to shape trust between economic players. Through our BV Green Line of services and solutions, we support our 400,000 clients to be more efficient, more methodical and more trustworthy in their journey towards more sustainable business and a more sustainable world. Together with Envision Digital, we will provide organizations with end-to-end solutions combining our respective strengths focused on achieving clients’ net-zero goals, and thus contribute to a positive impact on people and the planet. ”
While the number of organizations making net zero pledges has increased, there is also growing concern about the credibility of commitments that lean heavily on carbon offsets. In addition, increasing calls for greater transparency and accountability in emissions reporting have added another layer of difficulty on an organization’s road to net zero. The combination of Envision Digital’s AIoT technology and Bureau Veritas’ unrivalled expertise in sustainability certification and auditing processes will enable organisations to better align with internationally recognized carbon-neutral standards.
About Bureau Veritas
Bureau Veritas is a world leader in laboratory testing, inspection and certification services. Created in 1828, the Group has more than 78,000 employees located in more than 1,600 offices and laboratories around the globe. Bureau Veritas helps its 400,000 clients improve their performance by offering services and innovative solutions in order to ensure that their assets, products, infrastructure and processes meet standards and regulations in terms of quality, health and safety, environmental protection and social responsibility.
Bureau Veritas is listed on Euronext Paris and belongs to the Next 20 index.
Compartment A, ISIN code FR 0006174348, stock symbol: BVI.
For more information, visit www.bureauveritas.com
, and follow us on Twitter
(@bureauveritas) and LinkedIn
.
Our information is certified with blockchain technology.
Check that this press release is genuine at www.wiztrust.com
About Envision Digital
Envision Digital is committed to becoming the world’s leading net zero technology partner for enterprises, governments, and cities alike. Its world-class AIoT technology helps governments and companies across the world accelerate progress toward a net zero future and improve their citizens’ quality of life. Having established itself as a leading solutions provider for intelligent renewable energy generation, consumption efficiency and smart and flexible storage, Envision Digital has extended its capabilities beyond energy to enable and optimise applications – notably in smart renewables, city infrastructure and carbon management solutions.
EnOS™, Envision Digital’s proprietary AIoT operating system, connects and manages more than 110 million smart devices and 360 gigawatts of energy assets globally and with Envision Ark, it has earned Envision Group a place on Fortune’s 2021 Change The World list. Envision Digital’s growing ecosystem of more than 360 customers and partners spans 10 industries and includes Accenture, Amazon Web Services, GovTech Singapore, Keppel Corporation, Microsoft, Nissan, PTT, Solarvest, Total and ST Engineering. The company has close to 800 employees and 12 offices across China, France, Japan, Germany, Norway, the Netherlands, the United Kingdom, and the United States, with headquarters in Singapore.
For more information, please visit www.envision-digital.com/
View source version on businesswire.com: https://www.businesswire.com/news/home/20211108005906/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom